BIOGEN INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
BIOGEN INC. (BIIB) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $0.00 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-02-06
- BIOGEN INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $0.00.
- BIOGEN INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $0.00.
- BIOGEN INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $0.00.
- BIOGEN INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2019 was $50.03, a 7.09% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-06 |
| 2024-12-31 | $0.00 10-K · filed 2025-02-12 |
| 2023-12-31 | $0.00 10-K · filed 2024-02-14 |
| 2019-12-31 | $50.03 10-K · filed 2020-02-06 |
| 2018-12-31 | $53.85 10-K · filed 2019-02-06 |
| 2017-12-31 | $50.89 10-K · filed 2018-02-01 |
| 2016-12-31 | $53.75 10-K · filed 2017-02-02 |
| 2015-12-31 | $59.82 10-K · filed 2016-02-03 |
| 2014-12-31 | $53.46 10-K · filed 2015-02-04 |
| 2013-12-31 | $53.73 10-K · filed 2014-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |